Overview

Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer.

Status:
Not yet recruiting

Trial end date:
2023-02-28

Target enrollment:

Participant gender:

Summary

The primary purpose of this study is to determine the safety and recommended dose level (RDL) of BLEX 404 Oral Liquid combined with Docetaxel monotherapy in a 21-day schedule. The secondary purpose is to assess the efficacy and safety of BLEX 404 Oral Liquid combined with Docetaxel monotherapy.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

BioLite, Inc.

Treatments:

Docetaxel